Tardive Dyskinesia

WE MOVE makes every effort to present medical information that is up-to-date and accurate. The material provided has undergone rigorous medical review. Information regarding the authors, editors, publisher, and medical reviewers of this material of the WE MOVE Web site is listed below.

Medical science is constantly changing. Therefore, the authors, editors, and publisher do not warrant that the information in this text is complete, nor are they responsible for omissions or errors in the text or for the results of the use of this information. This information does not replace consultation with a physician. All medical procedures, drug doses, indications, and contraindications should be discussed with your personal physician.

Section Author: Catherine Friederich Murray, AMWA, NASW
Editorial Reviewer: Joy B. Leffler, NASW, AMIA
Medical Reviewers: Joseph Jankovic, MD and Mary Ann Richardson, PhD

Dr. Richardson holds the patent for the use of branched-chain amino acids for the treatment of tardive dyskinesia; all royalties are assigned to the State University system of New York.